Sutro Biopharma, Inc.

NASDAQ:STRO

Biotechnology

Healthcare
$8.50 +1.13%

+$0.32 today

Market cap
$141.11M
Beta
1.55
P/E (TTM)
-0.0
EPS (TTM)
-$1,174.12
52W Low $6.70High $43.85

Volume 0.31M

Average 0.28M

STRO Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Sutro Biopharma, Inc.NASDAQ: STRO

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $1.28M, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $1.28M. Over 3 fiscal years it compounded at -4.0% a year.

Context

  • Cost of revenue amounted to 7.1% of revenue in FY2025, down 4.5 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly cost of revenue holds near $1.28M or moves back toward the trailing-twelve-month quarterly average of $319.5K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.28M— QoQ
Last fiscal yearDec 2025
$7.32M+1.5% YoY
LTMMar 2026
$1.28M-28.6% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+1.5%——
3-year CAGR-4.0%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
7.32M USD
Year-over-year change
+1.5%
4-year CAGR
-7.0%

Cost of Revenue vs competitors

How STRO compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -28.6% is the 3rd highest of 5, against a peer median of -10.9%.
  • Cost of revenue amounts to 1.3% of revenue for STRO, versus a peer median of 92.5%.
STRO Competitors
Cost of Revenue for STRO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IFRXInflaRx N.V.LTM Mar 2026€7.26M EUR+133.7%—24746.3%
STTKShattuck Labs, Inc.LTM Mar 2026$1.82M USD-36.2%—182.0%
DTILPrecision BioSciences, Inc.LTM Mar 2026$1.37M USD——3.0%
STROSutro Biopharma, Inc.LTM Mar 2026$1.28M USD-28.6%-4.0%1.3%
PLRXPliant Therapeutics, Inc.LTM Mar 2026$711K USD+14.3%——
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$666K USD———
KLRSKalaris Therapeutics IncLTM Mar 2026$20K USD———
CNTBConnect Biopharma Holdings LimitedFY2025$0 USD——0.0%
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$0 USD-100.0%——
Peer median (excluding STRO) —-10.9%—92.5%

Competitors are the stored peer set for STRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue61.88M67.77M153.73M62.04M102.48M
Cost of Revenue9.77M8.29M6.82M7.22M7.32M
Gross Profit52.11M59.48M146.92M54.83M95.16M
Gross Margin84.2%87.8%95.6%88.4%92.9%
Research & Development104.4M137.17M180.43M252.04M166.42M
Selling, General & Admin56M59.54M62.58M48.45M41.02M
Operating Expenses150.63M188.43M236.19M293.28M200.11M
Depreciation & Amortization4.84M8.29M6.82M7.22M7.32M
EBITDA(97.56M)(105.07M)(67.92M)(180.45M)(145.65M)
EBITDA Margin-157.7%-155.0%-44.2%-290.9%-142.1%
Operating Income(98.52M)(128.94M)(89.28M)(238.45M)(104.95M)
Operating Margin-159.2%-190.3%-58.1%-384.3%-102.4%
Interest Income577K3.46M14.51M44.43M9.25M
Interest Expense3.14M3.35M23.75M31.07M38.21M
Other Income / Expenses(7.01M)12.24M677K13.36M(86.23M)
Income Before Tax(105.54M)(116.7M)(88.6M)(225.1M)(191.18M)
Pre-Tax Margin-170.6%-172.2%-57.6%-362.8%-186.5%
Income Tax Expense02.5M18.19M2.36M(93K)
Net Income(105.54M)(119.2M)(106.79M)(227.46M)(191.09M)
Net Margin-170.6%-175.9%-69.5%-366.6%-186.5%
EPS (Basic)(22.90)(23.50)(17.80)(29.60)(22.49)
EPS (Diluted)(22.90)(23.50)(17.80)(29.60)(22.49)
Weighted Avg Shares4.61M5.07M6.02M7.68M8.5M
Weighted Avg Shares (Diluted)4.61M5.07M6.02M7.68M8.5M

Sutro Biopharma, Inc.

NASDAQ:STRO

Intrinsic Alpha fair value

Locked

Current Price

$8.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.